On July 21, 2026 Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), reported that an abstract detailing the Phase 1 dose-escalation study of PAS-004 in patients with MAPK pathway-driven advanced solid tumors has been accepted for poster presentation in the Developmental Therapeutics track at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23-27, 2026, at the IFEMA Madrid Convention Center in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the Poster Presentation:
Title: Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors
Presenter: Kartik Krishnan, Miami, Florida, United States
Authors: Ildefonso I. Rodriguez Rivera (San Antonio, TX); Kartik Krishnan, Tiago Reis Marques, Joy Cannon, Yohana Sebhat (Miami, FL)
Abstract/Poster Number: 1050P
Session: Developmental Therapeutics
Date/Time: Friday, October 23, 2026, 15:15–16:00 CEST
The full abstract will be published on the ESMO (Free ESMO Whitepaper) Congress website in accordance with the meeting’s embargo policy. The Company plans to issue a follow-up release with detailed results at the time of presentation.
(Press release, Pasithea Therapeutics, JUL 21, 2026, View Source [SID1234669340])